Trouillas P, Chassard J L, Tommasi M, Aimard G, Devic M
Nouv Presse Med. 1978 Dec 9;7(44):4017-9.
The action of VM 26 on cerebral glioblastomas was suggested by studies of phase II or protocols in which the drug was used in association. The randomised protocol presented here, involving 10 treated subjects and 11 controls, showed that VM 26 was active in terms of the duration of survival of patients undergoing surgery for a glioblastoma. The mean survival was 16.4 months as against 9.6 months in the controls (statistically significant difference at p less than 0.05). This activity would tend to characterise the drug as one of the essential factors in the chemotherapy of all malignant gliomas, in particular since it is itself free of all haematological complications, even at high doses, and causes scarcely any allergic problems.
VM 26对脑胶质母细胞瘤的作用是通过II期研究或联合使用该药物的方案提出的。这里呈现的随机方案涉及10名接受治疗的受试者和11名对照，结果显示VM 26对于接受胶质母细胞瘤手术患者的生存时长有活性作用。平均生存期为16.4个月，而对照组为9.6个月（p小于0.05时具有统计学显著差异）。这种活性倾向于将该药物表征为所有恶性胶质瘤化疗的关键因素之一，特别是因为它本身即使在高剂量时也没有任何血液学并发症，并且几乎不会引起任何过敏问题。
